HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors

Biochemical Journal

Volumn 451, Issue 2, 2013, Pages 235-244

  Van Der Kraan, A Gabrielle J ^a,b   Chai, Ryan C C ^b   Singh, Preetinder P ^a   Lang, Benjamin J ^b   Xu, Jiake ^c   Gillespie, Matthew T ^a,b   Price, John T ^b   Quinn, Julian M W ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

17 allylamino demethoxygeldanamycin (17 AAG); Bone; Cell signal; Heat shock protein 90 (HSP90); Osteoclast; Osteolysis

Indexed keywords

4 [4 (1,4 BENZODIOXAN 6 YL) 5 METHYL 1H PYRAZOL 3 YL] 6 ETHYLRESORCINOL; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; HEAT SHOCK PROTEIN 90 INHIBITOR; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; TANESPIMYCIN; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MARROW CELL; BONE MARROW CULTURE; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; ONCOGENE C FOS; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ANIMALS; BENZOQUINONES; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; HETEROCYCLIC COMPOUNDS, 2-RING; HSP90 HEAT-SHOCK PROTEINS; ISOXAZOLES; LACTAMS, MACROCYCLIC; MICE; MICE, INBRED C57BL; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; PYRAZOLES; RESORCINOLS; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84875624867     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20121626     Document Type: Article

References (49)

1. Nakashima, T. and Takayanagi, H. (2011) New regulation mechanisms of osteoclast differentiation. Ann. N.Y. Acad. Sci. 1240, E13-E18
2. Iqbal, J., Sun, L. and Zaidi, M. (2009) Coupling bone degradation to formation. Nat. Med. 15, 729-731
3. Sharma, S. M., Bronisz, A., Hu, R., Patel, K., Mansky, K. C., Sif, S. and Ostrowski, M. C. (2007) MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J. Biol. Chem. 282, 15921-15929
4. Boyle, W. J., Simonet, W. S. and Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342
5. Guise, T. (2010) Examining the metastatic niche: targeting the microenvironment. Semin. Oncol. 37, S2-S14
6. Katagiri, T. and Takahashi, N. (2002) Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis. 8, 147-159
7. O'Brien, C. A. (2010) Control of RANKL gene expression. Bone 46, 911-919
8. Lu, S.-Y., Li, M. and Lin, Y.-L. (2010) Mitf induction by RANKL is critical for osteoclastogenesis. Mol. Biol. Cell 21, 1763-1771
9. Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R. et al. (1999) RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424
10. Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N. et al. (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191, 275-286
11. Yao, Z., Xing, L. and Boyce, B. F. (2009) NF-κB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J. Clin. Invest. 119, 3024-3034
12. Horwood, N. J., Elliott, J., Martin, T. J. and Gillespie, M. T. (1998) Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139, 4743-4746
13. Sells Galvin, R. J., Gatlin, C. L., Horn, J. W. and Fuson, T. R. (1999) TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem. Biophys. Res. Commun. 265, 233-239
14. Quinn, J. M. W., Itoh, K., Udagawa, N., Hausler, K., Yasuda, H., Shima, N., Mizuno, A., Higashio, K., Takahashi, N., Suda, T. et al. (2001) Transforming growth factor β affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16, 1787-1794
15. Porter, J. R., Fritz, C. C. and Depew, K. M. (2010) Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr. Opin. Chem. Biol. 14, 412-420
16. Whitesell, L. and Lindquist, S. L. (2005) HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761-772
17. Jhaveri, K., Taldone, T., Modi, S. and Chiosis, G. (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Biophys. Acta 1823, 742-755
18. Travers, J., Sharp, S. and Workman, P. (2012) HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discovery Today 17, 242-252
19. Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F. et al. (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68, 2850-2860
20. Yun, T. J., Harning, E. K., Giza, K., Rabah, D., Li, P., Arndt, J. W., Luchetti, D., Biamonte, M. A., Shi, J., Lundgren, K. et al. (2011) EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J. Immunol. 186, 563-575
21. Poulaki, V., Iliaki, E., Mitsiades, N., Mitsiades, C. S., Paulus, Y. N., Bula, D. V., Gragoudas, E. S. and Miller, J. W. (2007) Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J. 21, 2113-2123
22. Chen, G., Cao, P. and Goeddel, D. V. (2002) TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol. Cell 9, 401-410
23. Price, J. T., Quinn, J. M. W., Sims, N. A., Vieusseux, J., Waldeck, K., Docherty, S. E., Myers, D., Nakamura, A., Waltham, M. C., Gillespie, M. T. and Thompson, E. W. (2005) The heat shock protein 90 inhibitor, 17-allylamino-17- demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res. 65, 4929-4938
24. Yano, A., Tsutsumi, S., Soga, S., Lee, M. J., Trepel, J., Osada, H. and Neckers, L. (2008) Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc. Natl. Acad. Sci. U.S.A. 105, 15541-15546
25. Song, I., Kim, J. H., Kim, K., Jin, H. M., Youn, B. U. and Kim, N. (2009) Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett. 583, 2435-2440
26. Fox, S. W., Evans, K. E. and Lovibond, A. C. (2008) Transforming growth factor-β enables NFATc1 expression during osteoclastogenesis. Biochem. Biophys. Res. Commun. 366, 123-128
27. Yeung, Y. G., Jubinsky, P. T., Sengupta, A., Yeung, D. C. and Stanley, E. R. (1987) Purification of the colony-stimulating factor 1 receptor and demonstration of its tyrosine kinase activity. Proc. Natl. Acad. Sci. U.S.A. 84, 1268-1271
28. Tikellis, C., Xuereb, L., Casley, D., Brasier, G., Cooper, M. E. and Wookey, P. J. (2003) Calcitonin receptor isoforms expressed in the developing rat kidney. Kidney Int. 63, 416-426
29. Quinn, J. M., Whitty, G. A., Byrne, R. J., Gillespie, M. T. and Hamilton, J. A. (2002) The generation of highly enriched osteoclast-lineage cell populations. Bone 30, 164-170
30. Quinn, J. M., Morfis, M., Lam, M. H., Elliott, J., Kartsogiannis, V., Williams, E. D., Gillespie, M. T., Martin, T. J. and Sexton, P. M. (1999) Calcitonin receptor antibodies in the identification of osteoclasts. Bone 25, 1-8
31. Singh, P. P., van der Kraan, A. G., Xu, J., Gillespie, M. T. and Quinn, J. M. (2012) Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors. Biochem. Biophys. Res. Commun. 422, 48-53
32. Feng, H., Cheng, T., Steer, J. H., Joyce, D. A., Pavlos, N. J., Leong, C., Kular, J., Liu, J., Feng, X., Zheng, M. H. and Xu, J. (2009) Myocyte enhancer factor 2 and microphthalmia-associated transcription factor cooperate with NFATc1 to transactivate the V-ATPase d2 promoter during RANKL-induced osteoclastogenesis. J. Biol. Chem. 284, 14667-14676
33. Taldone, T., Sun, W. and Chiosis, G. (2009) Discovery and development of heat shock protein 90 inhibitors. Bioorg. Med. Chem. 17, 2225-2235
34. Taldone, T., Gozman, A., Maharaj, R. and Chiosis, G. (2008) Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8, 370-374
35. Smith, N. F., Hayes, A., James, K., Nutley, B. P., McDonald, E., Henley, A., Dymock, B., Drysdale, M. J., Raynaud, F. I. and Workman, P. (2006) Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Mol. Cancer Ther. 5, 1628-1637
36. Sharp, S. Y., Prodromou, C., Boxall, K., Powers, M. V., Holmes, J. L., Box, G., Matthews, T. P., Cheung, K.-M. J., Kalusa, A., James, K. et al. (2007) Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 6, 1198-1211
37. Sterling, J. A., Edwards, J. R., Martin, T. J. and Mundy, G. R. (2011) Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 48, 6-15
38. Zheng, Y., Zhou, H., Modzelewski, J. R., Kalak, R., Blair, J. M., Seibel, M. J. and Dunstan, C. R. (2007) Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res. 67, 9542-9548
39. Mundy, G. R. (1997) Mechanisms of bone metastasis. Cancer 80, 1546-1556
40. Pratt, W. B., Morishima, Y., Peng, H. M. and Osawa, Y. (2010) Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp. Biol. Med. 235, 278-289
41. Zhao, B., Grimes, S. N., Li, S., Hu, X. and Ivashkiv, L. B. (2012) TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J. Exp. Med. 209, 319-334
42. Neckers, L. and Workman, P. (2012) Hsp90 molecular chaperone inhibitors: are we there yet Clin. Cancer Res. 18, 64-76
43. Laramie, J. M., Chung, T. P., Brownstein, B., Stormo, G. D. and Cobb, J. P. (2008) Transcriptional profiles of human epithelial cells in response to heat: computational evidence for novel heat shock proteins. Shock 29, 623-630
44. Adachi, S., Yasuda, I., Nakashima, M., Yamauchi, T., Yamauchi, J., Natsume, H., Moriwaki, H. and Kozawa, O. (2010) HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells. Oncol. Rep. 23, 1709-1714
45. Fuller, K., Lean, J. M., Bayley, K. E., Wani, M. R. and Chambers, T. J. (2000) A role for TGFβ1 in osteoclast differentiation and survival. J. Cell Sci. 113, 2445-2453
46. Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-i. et al. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901
47. Asagiri, M. and Takayanagi, H. (2007) The molecular understanding of osteoclast differentiation. Bone 40, 251-264
48. Mansky, K. C., Sankar, U., Han, J. and Ostrowski, M. C. (2002) Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-κB ligand signaling. J. Biol. Chem. 277, 11077-11083
49. Kim, J. H., Jin, H. M., Kim, K., Song, I., Youn, B. U., Matsuo, K. and Kim, N. (2009) The mechanism of osteoclast differentiation induced by IL-1. J. Immunol. 183, 1862-1870